Author

Shibjyoti Debnath

Duke University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Evolutionary Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Jason A. SomarelliiD· 2 shared Aditya Agrawal· 1 shared Andrew J. ArmstrongiD· 1 shared Ayalur Raghu SubbalakshmiiD· 1 shared Jason Thomas GeorgeiD· 1 shared Kishore HariiD· 1 shared Mohit Kumar JollyiD· 1 shared Pelumi Olawuni· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Jason A. SomarelliORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems-level analysis identifies IRF6 as an inhibitor of epithelial-mesenchymal transition

Ayalur Raghu Subbalakshmi, Aditya Agrawal, Shibjyoti Debnath, Kishore Hari, Sarthak Sahoo, Jason A. Somarelli, Mohit Kumar Jolly

The paper identifies IRF6 as an inhibitor of epithelial-mesenchymal transition (EMT) through integrated computational and experimental analysis.

Journal of Biological Engineering · Jun 14, 2026Peer-reviewedSystems Biology

A memory-driven model of phenotypic adaptation for anticipating the emergence of enzalutamide resistance in prostate cancer

Zahra S. Ghoreyshi, Shibjyoti Debnath, Pelumi Olawuni, Andrew J. Armstrong, Jason A. Somarelli, Jason Thomas George

This paper develops a memory-driven model to predict enzalutamide resistance in prostate cancer by integrating reinforcement learning and clinical data, outperforming traditional models in capturing treatment dynamics and patient responses.

bioRxiv · Nov 3, 2025 · PreprintEvolutionary Biology